MS Speaks

Multiple Sclerosis => MS - RESEARCH AND NEWS => Topic started by: agate on February 15, 2018, 09:34:57 am

Title: (Abst.) Bryostatin-1 alleviates experimental MS
Post by: agate on February 15, 2018, 09:34:57 am

Abstract of "Bryostatin-1 alleviates experimental multiple sclerosis" by several Johns Hopkins researchers and published in PNAS (Proceedings of the National Academy of Sciences). From PubMed, February 15, 2018:


https://www.ncbi.nlm.nih.gov/pubmed/29440425


From the abstract:

Quote

More strikingly, bryo-1 reverses neurologic deficits after EAE onset, even when treatment is initiated at a late stage of disease when peak adaptive immunity has subsided.

And:

Quote

These findings suggest the potential for bryo-1 as a therapeutic agent in MS, particularly given its established clinical safety. Furthermore, the benefit of bryo-1, even in late treatment of EAE, combined with its targeting of innate myeloid cells suggests therapeutic potential in progressive forms of MS.